| Literature DB >> 25043588 |
Matthew R Sandbulte1, Ratree Platt1, James A Roth1, Jamie N Henningson2, Kathleen A Gibson3, Daniela S Rajão3, Crystal L Loving3, Amy L Vincent4.
Abstract
Live-attenuated influenza virus (LAIV) prime-boost vaccination previously conferred protection against heterologous H3N2 swine influenza challenge, including in piglets with maternally derived antibodies (MDA). Conversely, a whole-inactivated virus (WIV) vaccine was associated with enhanced disease. This study was aimed at identifying immune correlates of cross-protection. Piglets with and without MDA received intramuscular adjuvanted WIV or intranasal LAIV, and were challenged with heterologous H3N2. WIV induced cross-reactive IgG, inhibited by MDA, and a moderate T cell response. LAIV elicited mucosal antibodies and T cells cross-reactive to the heterologous challenge strain. The presence of MDA at LAIV vaccination blocked lung and nasal antibody production, but did not interfere with T cell priming. Even without mucosal antibodies, MDA-positive LAIV vaccinates were protected, indicating a likely role for T cells. Based on the data, one LAIV dose can induce cell-mediated immunity against antigenically divergent H3N2 influenza virus despite passive antibody interference with humoral immune responses. Published by Elsevier Inc.Entities:
Keywords: Heterologous immunity; Influenza A; Live attenuated influenza virus; Maternally derived antibodies; Whole inactivated virus
Mesh:
Substances:
Year: 2014 PMID: 25043588 DOI: 10.1016/j.virol.2014.06.027
Source DB: PubMed Journal: Virology ISSN: 0042-6822 Impact factor: 3.616